Document Detail


Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents.
MedLine Citation:
PMID:  21034401     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Vascular endothelial growth factor receptor (VEGFR) is an important receptor tyrosine kinase (RTK) in the induction of angiogenesis. Abnormal activation of VEGFR leads to several disorders including cancer. Nowadays, inhibition of VEGFR kinase has been one of the most powerful clinical strategies in cancer treatment and great efforts to design and synthesize small molecular VEGFR inhibitors for cancer research have been made in recent years. This review highlights the major progress and development of them, including their structure and pharmacophore features, biological activities and structure-activity relationships (SAR). Special attentions are paid to the compounds available in market or in advanced clinical stages.
Authors:
Dan Xu; Tianlin L Wang; Li-Ping Sun; Qi-Dong You
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Mini reviews in medicinal chemistry     Volume:  11     ISSN:  1875-5607     ISO Abbreviation:  Mini Rev Med Chem     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101094212     Medline TA:  Mini Rev Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  18-31     Citation Subset:  IM    
Affiliation:
Department of Medicinal Chemistry, China Pharmaceutical University, No. 24, Tongjiaxiang Rd, Nanjing, 210009, Jiangsu Province, P.R. China. youqidong@gmail.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  How can we reduce alcohol-related road crash deaths among young Australians?
Next Document:  Cardiovascular effects of glucagon-like Peptide 1.